loading page

Disparities and Therapeutic Advances in Cystic Fibrosis
  • John Palla
John Palla
Ann and Robert H Lurie Children's Hospital of Chicago

Corresponding Author:[email protected]

Author Profile


Cystic fibrosis has seen a multitude of therapeutic advances targeting its downstream effects. This has led to a steady increase in survival over the past few decades. The recent development of disease-modifying drugs targeting the underlying CFTR mutation has revolutionized treatment for CF. Despite these advances, individuals with CF who are racial and ethnic minorities, from low socioeconomic status, or female sex have worse clinical outcomes. The inequitable access to CFTR modulators from cost and/or genetic eligibility has the potential to further worsen the existing health disparities seen within the CF community.
04 Feb 2023Submitted to Pediatric Pulmonology
06 Feb 2023Assigned to Editor
06 Feb 2023Submission Checks Completed
06 Feb 2023Review(s) Completed, Editorial Evaluation Pending
05 Mar 2023Reviewer(s) Assigned
21 Apr 2023Editorial Decision: Accept